Microbion: Microbion reports topline data from Phase II study of DFI therapy
Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI. The post Microbion reports topline data from Phase II study of DFI therapy appeared first on Clinical Trials Arena.
Read full article »
Microbion is a Montana-based pharmaceutical company that develops and commercializes novel medicines for the treatment of chronic and antibiotic-resistant infections.
Read more